FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2766012016> ?p ?o ?g. }

• W2766012016 endingPage "307" @default.
• W2766012016 startingPage "300" @default.
• W2766012016 abstract "Current strategies to delineate the risk of serious drug-induced liver injury associated with drugs rely on assessment of serum biomarkers that have been utilized for many decades. In particular, serum alanine aminotransferase and total bilirubin levels are typically used to assess hepatic integrity and function, respectively. Parallel measurement of these biomarkers is utilized to identify patients with drug-induced hepatocellular jaundice (“Hy’s Law” cases) which carries at least a 10% risk of death or liver transplant. However, current guidelines regarding use of these biomarkers in clinical trials can put study subjects at risk for life-threatening drug-induced liver injury, or result in over estimation of risk that may halt development of safe drugs. In addition, pharmaceutical companies are increasingly being required to conduct large and expensive clinical trials to “defend” the safety of their new drug when results from smaller trials are inconclusive. Innovative approaches and some novel biomarkers are now being employed to maximize the value of traditional biochemical tests. DILIsym®, a product of the DILIsim Initiative, utilizes serial serum alanine aminotransferase values, along with serum biomarkers of apoptosis vs necrosis, to estimate percent hepatocyte loss and total bilirubin elevations resulting from loss of global liver function. The results from analyses conducted with DILIsym have been reported to the FDA to support the safety of entolimod and cimaglermin alfa after elevations in serum alanine aminotransferase and/or bilirubin halted clinical development. DILIsym can also be utilized to determine whether rises in serum conjugated and unconjugated bilirubin are consistent with mechanisms unrelated to toxicity ( i.e. inhibition of bilirubin transport or metabolism). In silico modeling of traditional and novel drug-induced liver injury biomarker data obtained in clinical trials may be the most efficient and accurate way to define the liver safety profile of new drug candidates. Impact statement Blood tests used in clinical trials to detect and monitor drug-induced liver injury (DILI) have not changed in half a century. These tests have several shortcomings: their use has not completely prevented clinical trial participants from risk of life-threatening DILI, they can give false positive results that halt the development of safe drug candidates, and they can create liver safety “concerns” that require large additional clinical trials to accurately define DILI risk. This review highlights the use of in silico modeling to improve interpretation of the blood tests currently available to detect DILI risk in new drug candidates. This approach is increasingly being applied in clinical trials to more precisely assess the degree of hepatocellular injury and its functional impact. This new approach holds the promise of more accurately defining DILI risk in smaller clinical trials." @default.
• W2766012016 created "2017-11-10" @default.
• W2766012016 creator A5014115297 @default.
• W2766012016 creator A5062878299 @default.
• W2766012016 date "2017-11-02" @default.
• W2766012016 modified "2023-09-23" @default.
• W2766012016 title "<i>In silico</i> modeling to optimize interpretation of liver safety biomarkers in clinical trials" @default.
• W2766012016 cites W1550119222 @default.
• W2766012016 cites W1974752855 @default.
• W2766012016 cites W1975440270 @default.
• W2766012016 cites W1975908064 @default.
• W2766012016 cites W1981815425 @default.
• W2766012016 cites W1988499440 @default.
• W2766012016 cites W2000066924 @default.
• W2766012016 cites W2000837493 @default.
• W2766012016 cites W2000966089 @default.
• W2766012016 cites W2005568622 @default.
• W2766012016 cites W2013040905 @default.
• W2766012016 cites W2017011289 @default.
• W2766012016 cites W2020508492 @default.
• W2766012016 cites W2032948054 @default.
• W2766012016 cites W2040780112 @default.
• W2766012016 cites W2044680278 @default.
• W2766012016 cites W2062534954 @default.
• W2766012016 cites W2075506578 @default.
• W2766012016 cites W2089707005 @default.
• W2766012016 cites W2128874766 @default.
• W2766012016 cites W2139969518 @default.
• W2766012016 cites W2143289568 @default.
• W2766012016 cites W2153804622 @default.
• W2766012016 cites W2168198006 @default.
• W2766012016 cites W2264055547 @default.
• W2766012016 cites W2579455025 @default.
• W2766012016 cites W2591627543 @default.
• W2766012016 cites W2604524922 @default.
• W2766012016 cites W2607063313 @default.
• W2766012016 cites W2759627007 @default.
• W2766012016 cites W4256642426 @default.
• W2766012016 cites W4320300927 @default.
• W2766012016 doi "https://doi.org/10.1177/1535370217740853" @default.
• W2766012016 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5813867" @default.
• W2766012016 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29096561" @default.
• W2766012016 hasPublicationYear "2017" @default.
• W2766012016 type Work @default.
• W2766012016 sameAs 2766012016 @default.
• W2766012016 citedByCount "20" @default.
• W2766012016 countsByYear W27660120162018 @default.
• W2766012016 countsByYear W27660120162019 @default.
• W2766012016 countsByYear W27660120162020 @default.
• W2766012016 countsByYear W27660120162021 @default.
• W2766012016 countsByYear W27660120162022 @default.
• W2766012016 crossrefType "journal-article" @default.
• W2766012016 hasAuthorship W2766012016A5014115297 @default.
• W2766012016 hasAuthorship W2766012016A5062878299 @default.
• W2766012016 hasBestOaLocation W27660120162 @default.
• W2766012016 hasConcept C126322002 @default.
• W2766012016 hasConcept C177713679 @default.
• W2766012016 hasConcept C2776637226 @default.
• W2766012016 hasConcept C2777513400 @default.
• W2766012016 hasConcept C2778456037 @default.
• W2766012016 hasConcept C2780035454 @default.
• W2766012016 hasConcept C2992208098 @default.
• W2766012016 hasConcept C2992872382 @default.
• W2766012016 hasConcept C512861765 @default.
• W2766012016 hasConcept C535046627 @default.
• W2766012016 hasConcept C71924100 @default.
• W2766012016 hasConcept C98274493 @default.
• W2766012016 hasConceptScore W2766012016C126322002 @default.
• W2766012016 hasConceptScore W2766012016C177713679 @default.
• W2766012016 hasConceptScore W2766012016C2776637226 @default.
• W2766012016 hasConceptScore W2766012016C2777513400 @default.
• W2766012016 hasConceptScore W2766012016C2778456037 @default.
• W2766012016 hasConceptScore W2766012016C2780035454 @default.
• W2766012016 hasConceptScore W2766012016C2992208098 @default.
• W2766012016 hasConceptScore W2766012016C2992872382 @default.
• W2766012016 hasConceptScore W2766012016C512861765 @default.
• W2766012016 hasConceptScore W2766012016C535046627 @default.
• W2766012016 hasConceptScore W2766012016C71924100 @default.
• W2766012016 hasConceptScore W2766012016C98274493 @default.
• W2766012016 hasIssue "3" @default.
• W2766012016 hasLocation W27660120161 @default.
• W2766012016 hasLocation W27660120162 @default.
• W2766012016 hasLocation W27660120163 @default.
• W2766012016 hasLocation W27660120164 @default.
• W2766012016 hasOpenAccess W2766012016 @default.
• W2766012016 hasPrimaryLocation W27660120161 @default.
• W2766012016 hasRelatedWork W1960951724 @default.
• W2766012016 hasRelatedWork W2349772872 @default.
• W2766012016 hasRelatedWork W2388634531 @default.
• W2766012016 hasRelatedWork W239464175 @default.
• W2766012016 hasRelatedWork W2907883410 @default.
• W2766012016 hasRelatedWork W2913199951 @default.
• W2766012016 hasRelatedWork W2950025759 @default.
• W2766012016 hasRelatedWork W3000874642 @default.
• W2766012016 hasRelatedWork W3013384091 @default.
• W2766012016 hasRelatedWork W3031958074 @default.
• W2766012016 hasVolume "243" @default.
• W2766012016 isParatext "false" @default.

• next